References
- Li Q, Guan X, Wu P, et al. Early transmission dynamics in wuhan, china, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199–1207.
- Center for Systems Science and Engineering. John Hopkins university and medicine 2020. [ cited 2020 Jun 20]. Available from: https://coronavirus.jhu.edu/map.html
- Coronovirus disease (COVID-19). situation reports: World Health Organisation 2020. [ cited 2020 Jun 20]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
- Sun K, Chen J, Viboud C. Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: a population-level observational study. Lancet Digit Health. 2020;2:e201–08.
- Guan W, Zheng-yi N, Hu Y, et al. Clinical characteristics of coronovirus disease 2019 in China. N Engl J Med. 2020;382:708–1720.
- Centre for Disease Control (CDC). Morbidity and mortality weekly report. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019-United States, February 12–March 28, 2020. [ cited 2020 May 2]. Available from: https://www.cdc.gov/mmwr/volumes/69/wr/mm6913e2.htm
- Wu Z, McGoogan J. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323:1239–1242.
- McIntosh K, Hirsch M, Bloom A Coronavirus disease 2019 (COVID-19): epidemiology, virology, clinical features, diagnosis, and prevention. UpToDate. Waltham, MA: UpToDate Inc. [ cited 2020 May 15]. Available from: https://www.uptodate.com
- Cao W, Taisheng L. COVID-19: towards understanding of pathogenesis. Cell Res. 2020;30:367–369.
- Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574.
- Jose R, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8:e46-e47.
- Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts. World Health Organisation (WHO) - Interim Guidance 17 March 2020. [ cited 2020 Jun 4]. Available from: https://www.who.int/publications-detail/home-care-for-patients-with-suspected-novel-coronavirus-(ncov)-infection-presenting-with-mild-symptoms-and-management-of-contacts
- Kim A, Gandhi R Coronavirus disease 2019 (COVID-19): management in hospitalized adults. UpToDate. Waltham, MA: UpToDate Inc. [ cited 2020 Mayl-20]. Available from: https://www.uptodate.com
- Considerations in adjusting public health and social measures in the context of COVID-World Health Organisation (WHO) - Interim Guidance [ updated 2020 Apr 16; cited 2020 May 5]. Available from: https://apps.who.int/iris/bitstream/handle/10665/331773/WHO-2019-nCoV-Adjusting_PH_measures-2020.1-eng.pdf
- Food and drug administration: COVID-19 related guidance documents. [ cited 2020 Apr 10]. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-related-guidance-documents-industry-fda-staff-and-other-stakeholders
- Medicines and Healthcare Products Regulatory Agency (MHRA). [ cited 2020 Apr 10]. Available from: https://www.gov.uk/coronavirus
- Therapeutics Good Administration (TGA): coronavirus (COVID-19) - Information on medicine and medical devices. [ cited 2020 May 20]. Available from: https://www.tga.gov.au/collection/covid-19
- Moher D, Liberati A, Tetzlaff J, et al.; The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
- Higgins JPT, Altman DG, Sterne JAC. 2011. Chapter 8: assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 6.0. The Cochrane Collaboration. Available from: www.cochrane-handbook.org
- von Elm E, Altman DG, Egger M, et al. STROBE initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;6:344–349.
- Murad M, Sultan S, Haffar S, et al. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23:60–63.
- Review Manager (RevMan). [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.
- Li Y, Xie Z, Lin W, et al. An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI). MedRxiv. DOI:10.1101/2020.03.19.20038984
- Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787–1799.
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
- Ye XT, Luo YL, Xia SC, et al. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur Rev Med Pharmacol Sci. 2020;24:3390–3396.
- Liu F, Xu A, Zhang Y, et al. Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis. 2020. DOI:10.1016/j.ijid.2020.03.013
- Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study. J Infect. 2020;81:e1-e5.
- Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606.
- Wang Z, Chen X, Lu Y, et al. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020;14:64–68.
- Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;15(395):507–513.
- Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069.
- Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;5:475–481.
- Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020;63:706–711.
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062.
- Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934.
- Tang X, Du R, Wang R, et al. Comparison of hospitalized patients with acute respiratory distress syndrome caused by COVID-19 and H1N1. Chest. 2020;158:195–205.
- Chen J, Qi T, Liu L, et al. Clinical progression of patients with COVID-19 in Shanghai, China. J Infect. 2020;80:e1-e6.
- Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31:894–901.
- Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020;80:388–393.
- Liu K, Chen Y, Lin R, et al. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J Infect. 2020 Mar 27. DOI:10.1016/j.jinf.2020.03.005
- Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar 27. DOI:10.1001/jamacardio.2020.1017
- Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323:1582.
- Shi H, Han X, Zheng C. Evolution of CT manifestations in a patient recovered from 2019 novel coronavirus (2019-nCoV) pneumonia in Wuhan, China. Radiology. 2020 Feb 7: 200269. DOI:10.1148/radiol.2020200269
- Wei J, Xu H, Xiong J, et al. 2019 novel coronavirus (COVID-19) pneumonia: serial computed tomography findings. Korean J Radiol. 2020;21:501–504.
- Chen D, Xu W, Lei Z, et al. Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report. Int J Infect Dis. 2020;93:297–299.
- Han W, Quan B, Guo W, et al. The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019. J Med Virol. 2020;92:461–463.
- Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–422.
- Inciardi RM, Lupi L, Zaccone G, et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar 27. DOI:10.1001/jamacardio.2020.1096
- Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv. 2020 Jan 1. DOI:10.1101/2020.03.22.20040758
- Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Mar 20:105949. DOI:10.1016/j.ijantimicag.2020.105949
- Borba MG, Val FF, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Network Open. 2020;3:e208857.
- Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Nat Acad Sci. 2020 Apr 29;117. 10970–10975.
- Ferrey AJ, Choi G, Hanna RM, et al. A case of novel coronavirus disease 19 in a chronic hemodialysis patient presenting with gastroenteritis and developing severe pulmonary disease. Am J Nephrol. 2020;51:337–342.
- Michot J, Albiges L, Chaput N, et al. Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Ann Oncol. 2020;31:961-964 doi: 10.1016/j.annonc.2020.03.300
- Zhang X, Song K, Tong F, et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv. 2020;4:1307–1310.
- Wang Y, Jiang W, He Q, et al. Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China. medRxiv. DOI:10.1101/2020.03.06.20032342
- Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020;212:416–420.
- Young BE, Ong SW, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020;323:1488.
- Lan L, Xu D, Ye G, et al. Positive RT-PCR test results in patients recovered from COVID-19. JAMA. 2020;323:1502.
- Lim J, Jeon S, Shin HY, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020. 35(6). DOI:10.3346/jkms.2020.35.e79
- Kim JY, Choe PG, Oh Y, et al. The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: implication for infection prevention and control measures. J Korean Med Sci. 2020;35:e61.
- Qiu H, Wu J, Hong L, et al. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis. 2020 Mar 25;20: 689–696.
- Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569–1578.
- Chen C, Huang J, Cheng Z, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. MedRxiv. 2020 Jan 1. DOI:10.1101/2020.03.17.20037432
- Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020 Mar 18. DOI:10.1016/j.eng.2020.03.007
- Kujawski SA, Wong KK, Collins JP, et al. First 12 patients with coronavirus disease 2019 (COVID-19) in the United States. medRxiv. 2020 Jan 1. DOI:10.1101/2020.03.09.20032896
- Lescure FX, Bouadma L, Nguyen D, et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis. 2020;20:697–706.
- Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382:929–936.
- Durante-Mangoni E, Andini R, Bertolino L, et al. Early experience with remdesivir in SARS-CoV-2 pneumonia. Infection. 2020 May 16: 1. DOI:https://dx.doi.10.1007%2Fs15010-020-01448-x
- Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19—preliminary report. N Engl J Med. 2020 May 22. DOI:10.1056/NEJMoa2007764
- Goldman JD, Lye DC, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020 May 27. DOI:10.1056/NEJMoa2015301
- Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382:2327–2336.
- Cheng SC, Chang YC, Chiang YL, et al. First case of coronavirus disease 2019 (COVID-19) pneumonia in Taiwan. J Formos Med Assoc. 2020 Feb 26. DOI:10.1016/j.jfma.2020.02.007
- Huang WH, Teng LC, Yeh TK, et al. novel coronavirus disease (COVID-19) in Taiwan: reports of two cases from Wuhan, China. J Microbiol Immunol Infect. 2019 Feb 19;2020. DOI:10.1016/j.jmii.2020.02.009
- Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID‐19: A single center experience. J Med Virol. 2020 Apr 6;92: 814–818.
- Mihai C, Dobrota R, Schröder M, et al. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD. Ann Rheum Dis. 2020;79:668–669.
- Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar 9. DOI:10.1093/cid/ciaa237
- Yao TT, Qian JD, Zhu WY, et al. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease‐19 treatment option. J Med Virol. 2020 Feb 27;92: 556–563.
- Yan D, Liu XY, Zhu YN, et al. Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infection. Medrxiv. 2020 Jan 1. DOI:10.1101/2020.03.22.20040832
- Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018;197:757–767.
- Yang Z, Liu J, Zhou Y, et al. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect. 2020 Apr 10;81:e13-e20.
- Horby P, Lim Shen W, Emberson J, et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. MedRxiv. DOI:10.1101/2020.06.22.20137273.
- First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19. [ cited 2020 Apr 15]. Available from: https://www.sanofi.com/-/media/Project/One-Sanofi-web/Websites/Global/Sanofi-COM/Home/media-room/press-releases/2020/2020-03-30-07-00-00-2008040-en.pdf
- ClinicalTrials.gov [Internet]. Cao Y (Dr). Qilu hospital of Shandong University, Karolinska Institutet. ID: NCT04305106. Bevacizumab in severe or critically severe patients with COVID-19 pneumonia-RCT (BEST-RCT). [ updated 2020 Mar 12; cited 2020 Apr 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT04305106
- Ying F First affiliated hospital of Fujian medical university. ID: NCT04280588. Fingolimod in COVID-19. [ updated 2020 Feb 21; [cited 2020 Apr 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT04280588
- Pitts TC Hudson medical. ID: NCT04288713. Eculizumab (Soliris) in Covid-19 infected patients (SOLID-C19). [ updated 2020 Feb 28; cited 2020 Apr 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT04288713
- Chen L, Xiong J, Bao L, et al. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20:398–400.
- Bhimraj A, Morgan R, Shumaker A, et al. Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19. Clinl Infect Dis. 2020:ciaa478. DOI:10.1093/cid/ciaa478
- National Institute of Health (NIH): COVID-19 treatment guidelines 2020. [ cited 2020 Jun 25]. Available from: https://www.covid19treatmentguidelines.nih.gov/
- Canadian Critical Care Society and Association of Medical Microbiology and Infectious Disease (AMMI) Canada. Clinical management of patients with moderate to severe COVID-19 - Interim guidance. [ updated 2020 Apr 2; cited 2020 Apr 25]. Available from: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/clinical-management-covid-19.html
- National COVID-19 clinical evidence taskforce: living guidelines. Australia; 2020 [cited 2020 May 20]. Available from: http://www.covid19evidence.net.au
- National institute for health and care excellence (NICE): COVID-19 rapid guidelines. United Kingdom; 2020 [cited 2020 Jun 24]. Available from: https://www.nice.org.uk/guidance/ng163
- Indian Council of Medical Research (ICMR): advisory on the use of hydroxychloroquine as prophylaxis for SARS-C0V-2 infection; 2020 [cited 2020 Jun 25]. Available from: https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf
- Ontario clinical practice guidelines for antimicrobial and immunomodulatory therapy in adult patients with COVID-19. [ cited 2020 Jun 20]. Available from: https://www.antimicrobialstewardship.com/covid-19
- FDA news release. Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine. [ cited 2020 Jun 15]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and
- FDA news release. Remdesivir by gilead sciences: FDA warns of newly discovered potential drug interaction that may reduce effectiveness of treatment. [ cited 2020 Jun 15]. Available from: https://www.fda.gov/safety/medical-product-safety-information/remdesivir-gilead-sciences-fda-warns-newly-discovered-potential-drug-interaction-may-reduce
- World Health Organization. SOLIDARITY clinical trial for COVID-19 treatments. Update on hydroxychloroquine. [ cited 2020 Jun 17]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments
- University of Oxford. press release: no clinical benefits from use of hydroxychloroquine in hospitalised patients with COVID-19. [ cited 2020 Jun 5]. Available from: http://www.ox.ac.uk/news/2020-06-05-no-clinical-benefit-use-hydroxychloroquine-hospitalised-patients-covid-19
- The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19 - Preliminary report. N Engl J Med 2020 July 17. DOI:10.1056/NEJMoa2021436.
- Mehra M, Ruschitzka F, Patel A. Retraction - Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020;395:1820.
- Zou X, Chen K, Zou J, et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14:185–192.
- Mehtra M, Desai S, Kuy S, et al. Retraction: cardiovascular disease, drug therapy, and mortality in COVID-19. N Engl J Med. 2020;382:2582.
- Gracia-Ramos E. Is the ACE2 overexpression a risk factor for COVID-19 infection? Arch Med Res. 2020;51:345–346.
- Freedberg D, Conigliaro J, Wang T, et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study. Gastroenterology. 2020. S0016-5085:34706-5. DOI:10.1053/j.gastro.2020.05.053
- Klok F, Kruip MJHA, van der Meer N, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Throm Res. 2020 April 30. DOI:10.1016/j.thromres.2020.04.041
- Montori V, Devereaux P, Adhikari N, et al. Randomized trials stopped early for benefit: a systematic review. JAMA. 2005;294:2203–2209.